Because no current therapy for type 2 diabetes offers disease-modifying capabilities, there is high unmet need for drugs that can effectively control the disease. DRG’s Type 2 Diabetes Unmet Need 2017 focuses on injectable agents: insulins and GLP-1 receptor agonists. In DRG’s view, currently marketed injectables have scope to further move up the treatment algorithm. Therefore, understanding physicians’ perspectives on these products is increasingly important. In this content we reveal which drug attributes drive endocrinologists’ prescribing and explore how current injectables compare across efficacy, safety, and delivery attributes.
- What are the treatment drivers and goals for type 2 diabetes?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for type 2 diabetes?
- What are the prevailing areas of unmet need and opportunity in type 2 diabetes?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new type 2 diabetes drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European endocrinologists fielded in March 2017.
Key companies: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi
Key drugs: Lantus, Basaglar, Toujeo, Tresiba, Trulicity, Victoza